Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155309 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
A Phase 2 study, sponsored by Repurposed Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02155309: Clinical Trial Phase 2 study, sponsored by Repurposed Therapeutics.
NCT02155309 is a Phase 2 study that was terminated before completion, run by Repurposed Therapeutics. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02155309, a Phase 2 study, was terminated before completion, sponsored by Repurposed Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
Part 1, the pharmacokinetic (PK) phase, will expand upon the pilot study conducted at Naval Medical Research Laboratory (NAMRL) and has the goal of determining bioavailability and time to Cmax in a larger representative sample. Part 2, the efficacy phase, is to determine the efficacy of the aqueous spray solution via exposure to a nausea-inducing stimulus.
Primary Outcome
During rotation, efficacy is measured by the number of head movements subjects are able to make (12 per minute). While seated yaw-axis rotating, a pre-recorded computerized voice informed subjects to make paced head tilts of 30 ̊ to the right and left at a rate of 0.125 Hz (right, center, left, and back to center over 16 seconds).
Interventions
- DRUG Placebo
- DRUG Scopolamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Why NCT02155309 stopped before completion
NCT02155309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02155309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02155309 about?
NCT02155309 is a clinical study titled "Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray". Part 1, the pharmacokinetic (PK) phase, will expand upon the pilot study conducted at Naval Medical Research Laboratory (NAMRL) and has the goal of determining bioavailability and time to Cmax in a larger representative sample. Part 2, the efficacy phase, is to determine the efficacy of the aqueous ...
What is the current status of trial NCT02155309?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2014-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02155309?
The interventions under investigation include: Placebo (DRUG), Scopolamine (DRUG).
Who is sponsoring clinical trial NCT02155309?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02155309's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia